We are live on ! Find out more
NAGE

Niagen Bioscience

96 hedge funds and large institutions have $211M invested in Niagen Bioscience in 2021 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 24 increasing their positions, 33 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

177% more capital invested

Capital invested by funds: $76.2M → $211M (+$135M)

81% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 16

16% more funds holding

Funds holding: 8396 (+13)

8.16% more ownership

Funds ownership: 25.68%33.84% (+8.2%)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

11% less call options, than puts

Call options by funds: $8.87M | Put options by funds: $9.92M

27% less repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 33

Holders
96
Holders Change
+13
Holders Change %
+15.66%
% of All Funds
1.68%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
29
Increased
24
Reduced
33
Closed
16
Calls
$8.87M
Puts
$9.92M
Net Calls
-$1.05M
Net Calls Change
-$1.1M

NAGE Hedge Fund Activity: Q1 2021 in Review

96 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Niagen Bioscience (NAGE) for Q1 2021, worth a combined $211M — up 177% from $76.2M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new NAGE positions and 16 closed out — a net gain of 13 holders — while 24 added to existing stakes and 33 trimmed.

The largest buyer was Yong Rong (HK) Asset Management, opening a new position worth an estimated $32.7M. The largest seller was Tieton Capital Management, cutting an estimated $6.68M.

  • 96 institutional investors held Niagen Bioscience (NAGE) as of Q1 2021, up from 83 in Q4 2020.
  • Funds reported $211M of Niagen Bioscience stock for Q1 2021, up 177% quarter-over-quarter.
  • 29 funds opened new Niagen Bioscience positions in Q1 2021 and 16 closed out, a net change of +13 holders.
  • The largest Niagen Bioscience buyer in Q1 2021 was Yong Rong (HK) Asset Management, an estimated $32.7M added.
  • The largest Niagen Bioscience seller in Q1 2021 was Tieton Capital Management, an estimated $6.68M sold.

Based on aggregated 13F filings for Q1 2021.